NCT05539339尚未招募不适用
Molecular Profiling of Tumor in Situ Fluid in Guiding Individualized Treatment Plan in Adults With ctDNA-level-relapse Glioblastoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Progression-free survival at 6 months
研究概览
简要总结
Tumor in situ fluid (TISF) refers to the fluid within the surgical cavity of patients with glioblastoma. Postoperative serial TISF is collected for circulating tumor DNA (ctDNA) analysis and identifying ctDNA-level relapse driven by one or a set of specific genomic alterations before overt imaging recurrence of the tumor. This single-arm open-label prospective pilot feasibility trial recruiting 20 adult patients with ctDNA-level-relapse glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their serial TISF ctDNA. It will be aimed to test whether the personalized intervention can prolong the progression-free and overall survival and the feasibility of conducting a full-scale trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent and HIPAA authorization obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations
- •Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study, including disease assessment by MRI and tumor in situ fluid (TISF) collection
- •Histologically confirmed diagnosis of glioblastoma
- •Resection surgery done at the study center (Henan Provincial People's Hospital), with a reservoir intraoperatively implanted connecting the surgical cavity and the subscalp for postoperative noninvasive TISF collection
- •Previous first line treatment with at least radiotherapy
- •An interval of > 28 days and full recovery (i.e., no ongoing safety issues) from surgical resection prior to grouping
- •Karnofsky performance status (KPS) of 70 or higher
- •Life expectancy > 12 weeks
排除标准
- •More than two recurrences of GBM
- •Presence of extracranial metastatic, significant leptomeningeal disease or tumors primarily localized to the brainstem or spinal cord
- •Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
- •Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring chronic and systemic immunosuppressive treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Subjects have any other condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 14 days. Inhaled or topical steroids and adrenal replacement doses >10mg daily prednisone equivalent are permitted in absence of active autoimmune disease
- •Previous radiation therapy with anything other than standard radiation therapy (i.e., focally directed radiation) administered as first line therapy
- •Previous treatment with carmustine wafer except when administered as first line treatment and at least 6 months prior to randomization
- •Previous bevacizumab or other VEGF or anti-angiogenic treatment
- •Previous treatment with a PD-1, PD-L1 or CTLA-4 targeted therapy
- •Evidence of > Grade 1 CNS hemorrhage on the baseline MRI scan
- •Inadequately controlled hypertension (defined as systolic blood pressure ≥160 mmHg and /or diastolic blood pressure ≥100 mmHg) within 7 days of first study treatment
- •Prior history of hypertensive crisis, hypertensive encephalopathy, reversible posterior leukoencephalopathy syndrome (RPLS)
- •Prior history of gastrointestinal diverticulitis, perforation, or abscess
- •Clinically significant (i.e., active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment
- •Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment. Any previous venous thromboembolism ≥ NCI CTCAE Grade 3 within 3 months prior to start of study treatment
- •History of pulmonary hemorrhage/hemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month prior to randomization
- •History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)
- •Current or recent (within 10 days of study enrollment) use of anticoagulants that, in the opinion of the investigator, would place the subject at significant risk for bleeding. Prophylactic use of anticoagulants is allowed
- •Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study
- •Minor surgical procedure (e.g., stereotactic biopsy within 7 days of first study treatment; placement of a vascular access device within 2 days of first study treatment)
- •History of intracranial abscess within 6 months prior to randomization;
- •History of active gastrointestinal bleeding within 6 months prior to randomization
- •Serious, non-healing wound, active ulcer, or untreated bone fracture
- •Subjects unable (due to existent medical condition, e.g., pacemaker or ICD device) or unwilling to have a head contrast enhanced MRI
- •Positive test for hepatitis B virus surface antigen (HBV sAg) or detectable hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection
- •Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- •History of severe hypersensitivity reaction to any monoclonal antibody
- •Patients that require decadron > 4 mg/ day or equivalent of steroids
结局指标
主要结局
Progression-free survival at 6 months
时间窗: Up to six months after beginning treatment
The proportion of participants in the analysis population who remain progression-free for at least six months following initiation of study therapy.
Overall survival rate at 18 months
时间窗: Up to 18 months after beginning therapy
OS-18 is the proportion of participants in the analysis population who remain alive for at least twelve months following initiation of study therapy.
次要结局
- Overall survival(Up to 3 years after beginning treatment)
- Progression-free survival(Up to 3 years after beginning treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The Roles of Tissue Factor in Malignant GliomasBrain TumorsVenous ThromboembolismNCT00201903Ontario Clinical Oncology Group (OCOG)30
尚未招募
不适用
Liquid Biopsy for the Diagnosis of Intestinal-type Adenocarcinoma of the Ethmoid (BLADE)Ethmoid Sinus TumorAdenocarcinomaCirculating Tumor CellNCT06090214University Hospital, Montpellier42
已完成
不适用
Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid DetectionGlioma, MalignantNCT04904419Jinsong Wu137
Unknown
1 期
TMTP1-ICG Mapping in Colposcopy-directed BiopsyCervical Intraepithelial NeoplasiaNCT03321461Huazhong University of Science and Technology40
招募中
不适用
NovoTTF Treatment Signatures in Glioblastoma Patients At AutopsyGlioblastomaNCT03194971Medical College of Wisconsin20